SAN DIEGO — At the Ophthalmology Innovation Summit here, Matthew Chapin, senior vice president of corporate development at Ora Inc., discusses a panel in which he participated on alternative financing models for companies in early ophthalmology product development.
SAN DIEGO — At the Ophthalmology Innovation Summit here, John Maroney, CEO of ForSight Vision5, discusses the company’s products aimed at eliminating glaucoma medication eye drops with a drug delivery device that will avoid compliance issues with patients with glaucoma.
SAN DIEGO — At the Ophthalmology Innovation Summit, Daniel S. Durrie, MD, announces the merger of Durrie Vision Research with the Hoopes-Rivera Clinical Research Center. He also discusses the new discussion centered around dysfunctional lens syndrome during the ASCRS meeting being held here.
SAN DIEGO — At the Ophthalmology Innovation Summit here, Thomas A. Mitro, president and COO of Aerie Pharmaceuticals, discusses the company’s two glaucoma products in the pipeline. Rhopressa is currently in three phase 3 clinical trials, while Roclatan has completed phase 2b and the company plans to begin phase 3 trials in 2015.
From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and legislative topics that weigh on the minds of today’s physicians and health care executives.Just hours ago, President Obama signed into law the “Medicare Access and CHIP Reauthorization Act of 2015,” which permanently repeals the long-maligned Sustainable Growth Rate (SGR) payment formula.
SAN DIEGO — At the Ophthalmology Innovation Summit here, James V. Mazzo discusses a recurring panel discussion he moderates called “Masters of the Universe,” which brings together industry leaders in ophthalmology to discuss the challenges and opportunities facing large ophthalmology companies in the current financial and regulatory atmosphere.